Management of urinary tract infections from multidrug-resistant organisms

Infectious Disease Clinics of North America

Volumn 28, Issue 1, 2014, Pages 49-59

  Gupta, Kalpana ^a,b   Bhadelia, Nahid ^b  

^a Infectious Disease Service   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbapenem resistant Enterobacteriaceae; Cystitis; Extended spectrum lactamases; Multidrug resistant organisms; Vancomycin resistant Enterococcus

Indexed keywords

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CYSTITIS; EXTENDED-SPECTRUM Β-LACTAMASES; MULTIDRUG-RESISTANT ORGANISMS; VANCOMYCIN-RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; DISEASE MANAGEMENT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI INFECTIONS; HUMANS; STAPHYLOCOCCAL INFECTIONS; URINARY TRACT INFECTIONS;

EID: 84895073236     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2013.10.002     Document Type: Review

References (60)

1. Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003, 36(5):592-598.
2. Cosgrove S.E., Kaye K.S., Eliopoulous G.M., et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002, 162(2):185-190.
3. Stosor V., Peterson L.R., Postelnick M., et al. Enterococcus faecium bacteremia: does vancomycin resistance make a difference?. Arch Intern Med 1998, 158(5):522-527.
4. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42(Suppl 2):S82-S89.
5. Doi Y., Park Y.S., Rivera J.I., et al. Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013, 56(5):641-648.
6. Huttner B., Jones M., Rubin M.A., et al. Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs medical centers, 2005-2010. PLoS One 2012, 7(5):e36649.
7. Gupta K., Scholes D., Stamm W.E. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999, 281(8):736-738.
8. Pitout J.D., Church D.L., Gregson D.B., et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother 2007, 51(4):1281-1286.
9. Pitout J.D., Hanson N.D., Church D.L., et al. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis 2004, 38(12):1736-1741.
10. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8(3):159-166.
11. Calbo E., Romani V., Xercavins M., et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. JAntimicrob Chemother 2006, 57(4):780-783.
12. Ho P.L., Poon W.W., Loke S.L., et al. Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women. JAntimicrob Chemother 2007, 60(1):140-144.
13. Ho P.L., Wong R.C., Yip K.S., et al. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes. Diagn Microbiol Infect Dis 2007, 59(4):439-445.
14. Lewis J.S., Herrera M., Wickes B., et al. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007, 51(11):4015-4021.
15. Rodriguez-Bano J., Navarro M.D., Romero L., et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. JClin Microbiol 2004, 42(3):1089-1094.
16. Rodriguez-Bano J., Navarro M.D., Romero L., et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006, 43(11):1407-1414.
17. Woodford N., Ward M.E., Kaufmann M.E., et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. JAntimicrob Chemother 2004, 54(4):735-743.
18. Kang C.I., Cheong H.S., Chung D.R., et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2008, 27(1):85-88.
19. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013, 62(9):165-170.
20. Hidron A.I., Edwards J.R., Patel J., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29(11):996-1011.
21. Shepherd A.K., Pottinger P.S. Management of urinary tract infections in the era of increasing antimicrobial resistance. Med Clin North Am 2013, 97(4):737-757.
22. Zhanel G.G., Laing N.M., Nichol K.A., et al. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). JAntimicrob Chemother 2003, 52(3):382-388.
23. Swaminathan S., Alangaden G.J. Treatment of resistant enterococcal urinary tract infections. Curr Infect Dis Rep 2010, 12(6):455-464.
24. Karki S., Land G., Aitchison S., et al. Long term carriage of vancomycin-resistant enterococci in patients discharged from hospital: a 12-year retrospective cohort study. JClin Microbiol 2013, 51(10):3374-3379.
25. Mandell G.L., Bennett J.E., Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2010, Churchill Livingstone/Elsevier, Philadelphia. 7th edition.
26. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008, 14(Suppl 1):198-202.
27. Widerstrom M., Wistrom J., Ferry S., et al. Molecular epidemiology of Staphylococcus saprophyticus isolated from women with uncomplicated community-acquired urinary tract infection. JClin Microbiol 2007, 45(5):1561-1564.
28. Chang S., Sievert D.M., Hageman J.C., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. NEngl J Med 2003, 348(14):1342-1347.
29. Beerepoot M.A., den Heijer C.D., Penders J., et al. Predictive value of Escherichia coli susceptibility in strains causing asymptomatic bacteriuria for women with recurrent symptomatic urinary tract infections receiving prophylaxis. Clin Microbiol Infect 2012, 18(4):E84-E90.
30. Foxman B. Editorial commentary: extended-spectrum beta-lactamase-producing Escherichia coli in the United States: time to rethink empirical treatment for suspected E. coli infections?. Clin Infect Dis 2013, 56(5):649-651.
31. Auer S., Wojna A., Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010, 54(9):4006-4008.
32. Falagas M.E., Vouloumanou E.K., Togias A.G., et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. JAntimicrob Chemother 2010, 65(9):1862-1877.
33. Oteo J., Bautista V., Lara N., et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. JAntimicrob Chemother 2010, 65(11):2459-2463.
34. Gupta K., Hooton T.M., Naber K.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52(5):e103-e120.
35. Prakash V., Lewis J.S., Herrera M.L., et al. Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2009, 53(3):1278-1280.
36. Ramphal R., Ambrose P.G. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006, 42(Suppl 4):S164-S172.
37. Keating G.M., Perry C.M. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005, 65(15):2151-2178.
38. Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. JClin Microbiol 2008, 46(5):1892-1893.
39. Korth-Bradley J.M., Troy S.M., Matschke K., et al. Tigecycline pharmacokinetics in subjects with various degrees of renal function. JClin Pharmacol 2012, 52(9):1379-1387.
40. Krueger W.A., Kempf V.A., Peiffer M., et al. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. JClin Microbiol 2008, 46(2):817-820.
41. Satlin M.J., Kubin C.J., Blumenthal J.S., et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011, 55(12):5893-5899.
42. Sandri A.M., Landersdorfer C.B., Jacob J., et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013, 57(4):524-531.
43. Lee G.C., Burgess D.S. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 2012, 11:32.
44. Daikos G.L., Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect 2011, 17(8):1135-1141.
45. Warren J.W., Abrutyn E., Hebel J.R., et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999, 29(4):745-758.
46. Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997, 53(4):637-656.
47. Naber K.G., Bartnicki A., Bischoff W., et al. Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents 2004, 23(Suppl 1):S41-53.
48. Linden P.K. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002, 62(3):425-441.
49. Pogue J.M., Paterson D.L., Pasculle A.W., et al. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2007, 28(12):1382-1388.
50. Eisenstein B.I. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs 2004, 13(9):1159-1169.
51. Livermore D.M., Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. JAntimicrob Chemother 2013, 68(8):1825-1831.
52. Endimiani A., Choudhary Y., Bonomo R.A. Invitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009, 53(8):3599-3601.
53. Goldstein E.J., Citron D.M., Tyrrell K.L., et al. Invitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria. Antimicrob Agents Chemother 2013, 57(6):2620-2630.
54. Hirsch E.B., Ledesma K.R., Chang K.T., et al. Invitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2012, 56(7):3753-3757.
55. Mushtaq S., Woodford N., Hope R., et al. Activity of BAL30072 alone or combined with beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. JAntimicrob Chemother 2013, 68(7):1601-1608.
56. Ishii Y., Eto M., Mano Y., et al. Invitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2010, 54(9):3625-3629.
57. Zhanel G.G., Lawson C.D., Adam H., et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs 2013, 73(2):159-177.
58. Boucher H.W., Talbot G.H., Benjamin D.K., et al. 10 x '20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013, 56(12):1685-1694.
59. Perez F., Bonomo R.A. Can we really use ss-lactam/ss-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ss-lactamase-producingbacteria?. Clin Infect Dis 2012, 54(2):175-177.
60. Bush K., Pucci M.J. New antimicrobial agents on the horizon. Biochem Pharmacol 2011, 82(11):1528-1539.